• 1. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 2. Enantiomeric two-fold interpenetrated 3D zinc(ii) coordination networks as a catalytic platform: significant difference between water within the cage and trace water in transesterification?
  Eunkyung Choi,Minjoo Ryu,Haeri Lee,Ok-Sang Jung Dalton Trans., 2017,46, 4595-4601
• 3. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 4. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoindoles and derivatives Isoindolones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isoindoles and derivatives Isoindolines Isoindolones

Recent Advances in the Application of 5-(Tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-1-one (CAS: 376584-62-2) in Chemical Biology and Drug Discovery

The compound 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-1-one (CAS: 376584-62-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This boronic acid derivative, characterized by its unique structural features, has demonstrated promising potential in various applications, including proteolysis-targeting chimeras (PROTACs), kinase inhibition, and as a versatile intermediate in organic synthesis. Recent studies have highlighted its role in facilitating the development of novel therapeutic agents, particularly in oncology and neurodegenerative diseases.

One of the key attributes of this compound is its ability to serve as a boron-containing building block in medicinal chemistry. The tetramethyl-1,3,2-dioxaborolane moiety enhances the stability and reactivity of the molecule, making it an ideal candidate for Suzuki-Miyaura cross-coupling reactions. This property has been exploited in the synthesis of complex bioactive molecules, where the introduction of boron atoms can significantly alter the pharmacokinetic and pharmacodynamic profiles of the resulting compounds. Recent publications in journals such as the Journal of Medicinal Chemistry and ACS Chemical Biology have detailed its use in the construction of boron-based inhibitors targeting key enzymes involved in disease pathways.

In the context of drug discovery, 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-1-one has been investigated for its potential as a PROTAC warhead. PROTACs are bifunctional molecules that recruit E3 ubiquitin ligases to degrade target proteins, and the boronic acid group in this compound has shown high affinity for specific protein targets. A 2023 study published in Nature Chemical Biology demonstrated its efficacy in degrading oncogenic proteins, such as BTK and EGFR, in preclinical models. The study reported that the compound's boronate ester functionality facilitated reversible binding to target proteins, enabling efficient degradation without off-target effects.

Furthermore, the compound's utility extends to the field of chemical biology, where it has been employed as a probe for studying protein-protein interactions and enzyme mechanisms. Its fluorescent derivatives have been used in high-throughput screening assays to identify novel modulators of disease-relevant pathways. Recent advancements in imaging techniques, such as positron emission tomography (PET), have also leveraged the compound's boron isotope (10B) for neutron capture therapy in cancer treatment. These applications underscore its versatility and highlight its potential as a multifunctional tool in both research and clinical settings.

Despite its promising applications, challenges remain in optimizing the delivery and bioavailability of boron-containing compounds. Recent research has focused on developing prodrug strategies and nanoparticle-based delivery systems to enhance the therapeutic index of 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-1-one. A 2024 study in Advanced Drug Delivery Reviews proposed the use of liposomal encapsulation to improve its solubility and target specificity, addressing some of the limitations associated with boron-based therapeutics.

In conclusion, 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-1-one (CAS: 376584-62-2) represents a valuable scaffold in modern drug discovery and chemical biology. Its unique chemical properties and diverse applications make it a focal point of ongoing research, with potential implications for the development of next-generation therapeutics. Future studies are expected to explore its role in combination therapies and precision medicine, further solidifying its position as a critical tool in the fight against complex diseases.

• 171364-80-0(Methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate)
• 210907-84-9(3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)aniline)
• 214360-57-3(N-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide)
• 380430-66-0(2-2-(4,4,5,5-Tetramethyl-1,3,2dioxaborolan-2-yl)-benzyl-isoindole-1,3-dione)
• 138500-86-4(2-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetonitrile)
• 223595-20-8((R)-5-(1,3,6,2-Dioxazaborocan-2-yl)-1-methyl-2-tritylisoindoline)
• 128376-65-8(4-(5,5-Dimethyl-1,3,2-dioxaborinan-2-yl)benzaldehyde)
• 214360-73-3(4-Aminophenylboronic acid pinacol ester)
• 269409-73-6(3-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid)
• 1004294-80-7(6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-1-one)